Le Lézard
Classified in: Health, Business
Subjects: ECO, FDA

Vermillion Announces Publication of Foundational Health Economics Study


AUSTIN, Texas, Nov. 16, 2017 /PRNewswire/ -- Vermillion (NASDAQ: VRML) announced today the acceptance and publication of a novel paper, "Economic Impact of Increased Utilization of Multivariate Assay Testing to Guide the Treatment of Ovarian Cancer: Implications for Payers" in the journal American Health and Drug Benefits.

The paper details the base case of a budget impact model that dynamically tracks the effect of OVA1 adoption in lieu of CA125 in the appropriate patient population on overall cost, both at a plan and per member per month (PMPM) level.  Claims data from a total of over 92,000 health plan members, comprising over 48,000 commercially insured members and 44,000 Medicare beneficiaries, were used in the development of the model. Sensitivity analysis revealed potential savings of up to $0.17 PMPM for commercially insured patients and up to $0.05 for Medicare beneficiaries. These results of the budget impact model base case support the use of OVA1 instead of CA125, by indicating that cost-savings can be achieved, while reaping the clinical benefits of improved diagnostic accuracy, early disease detection, and reductions in multiple, and possibly non-medically necessary, referrals to gynecologic oncologists.

"Practicing in today's healthcare environment requires doctors to provide the highest standard of care that remains cost effective and improves evidence based outcomes," stated Dr. Burton Brodsky, Director of Minimally Invasive Surgery, Section Chief Gynecological Services, and Assistant Clinical Professor at the University of Toledo, who is also one of the co-authors of this paper. "OVA1 can accomplish all these important health care parameters for women having surgery for a pelvic mass".

Ovarian cancer will affect over 22,000 U.S. women in 2017 (1), greater than 200,000 women globally (2), and has the lowest survival rate of all gynecological cancers, with a 5 year survival rate of less than 50% (1).  Earlier detection and proper care pathways increase the chance of survival and patient outcomes(3-5), which has been the primary mission of Vermillion/ ASPiRA Labs since OVA1 (MIA) was first launched in 2010. The appropriate referral of patients who are at high risk for ovarian cancer is necessary for optimal outcomes; however, referral of benign cases can increase wait times for a specialist visit and often, if not medically necessary, can increase anxiety and other burdens to the patient. Using all preoperative information available to the clinician, which includes symptoms, family history, physical exam, ultrasound findings, and OVA1 (MIA) results can facilitate the appropriate triage of patients with a pelvic mass either to the gynecologic oncologist or to remain with their OB/Gyn provider for care and surgery.

"Vermillion is dedicated to working towards improving the lives and outcomes for women with ovarian cancer while doing our part to keep appropriate cost of care effective for everyone. We are very encouraged by the results of this latest study." Stated Marra Francis, MD, FACOG, CMO of Vermillion.

OVA1 (MIA) is now considered a Level B Recommendation by ACOG(6). Based on its support by ACOG, NCCN update and SGO positive position statement, OVA1 (MIA)  can be the physician's first choice in biomarker panels to best triage their pelvic masses to the most appropriate care pathway. There is no other comparable technology on the market today.

About Vermillion
Vermillion, Inc. is dedicated to the discovery, development and commercialization of novel high-value diagnostic and bio-analytical solutions that help physicians diagnose, treat and improve gynecologic health outcomes for women. Vermillion, along with its prestigious scientific collaborators, discovers, develops, and delivers innovative diagnostic and technology tools that help women with serious diseases.  The company's initial in vitro diagnostic test, OVA1® (MIA), was the first FDA-cleared, protein-based In Vitro Diagnostic Multivariate Index Assay, and represented a new class of software-based liquid biopsy in vitro diagnostics. In March 2016, Vermillion received FDA clearance for Overatm, a Multivariate Index Assay 2nd Generation (MIA2G) test with significantly improved specificity and ease of use. For additional information, including published clinical trials, visit www.vermillion.com.

About OVA1® and Overatm

Investor Relations Contact:
Michael Wood
LifeSci Advisors LLC
Tel 1-646-597-6983
[email protected]

1.              www.cancer.gov/types/ovarian
2.              www.wcrf.org/int/cancer-facts-figures/data-specific-cancers/ovarian-cancer-statistics
3. Chan JK, Kapp DS, Shin JY, et al. Influence of the gynecologic oncologist on the survival of ovarian cancer patients. Obstet Gynecol. 2007;109:1342Y1350.
4. Engelen MJ  ,Kos HE,Willemse PH,etal. Surgery by consultant gynecologic oncologists improves survival in patients with ovarian carcinoma. Cancer. 2006;106:589Y598.
5. Vernooij F,Heintz  P,Witteveen E,etal.The outcomes of ovarian cancer treatment are better when provided by gynecologic oncologists and in specialized hospitals: a systematic review. Gynecol Oncol. 2007;105:801Y812
6. American College of Obstetricians and Gynecologists. ACOG Practice Bulletin. Management of adnexal masses. Obstet Gynecol. 2016; 128: e210-26.

 

SOURCE Vermillion, Inc.


These press releases may also interest you

at 07:30
AGF Investments Inc. (AGF Investments)  today announced the proposed termination of AGF Global Opportunities Bond ETF (ticker: AGLB), AGF Systematic Canadian Equity ETF (ticker: QCD) and AGF Systematic Emerging Markets Equity ETF (ticker: QEM) (each...

at 07:26
GOL Linhas Aéreas Inteligentes S.A. ("GOL" or "Company") , one of the leading airlines in Brazil and part of the Abra Group, today announced its consolidated results for the fourth quarter of 2023 (4Q23). The Company remained focused on operational...

at 07:24
Ericsson today announced that on March 28, 2024, the independent compliance Monitor appointed by the U.S. Department of Justice (DOJ) (in June of 2020 in connection with Ericsson's resolution of historical violations of the Foreign Corrupt Practices...

at 07:15
SinglePoint Inc (CBOE: SING) ("SinglePoint" or "the Company") subsidiary Boston Solar, a proud partner of the Boston Red Sox and a leading provider of solar energy solutions, proudly announces their transformative solar installation project at Pelham...

at 07:15
Kraken Technology Group, a maritime technology leader specializing in the disruptive design and manufacturing of high-performance platforms, and Auterion, the company building the software-defined future for mobile robotics and powering the world's...

at 07:10
D-Wave Quantum Inc., ("D-Wave" or the "Company") a leader in commercial quantum computing systems, software, and services, today announced financial results for its fourth fiscal quarter and year ended December 31, 2023. "Our momentum is...



News published on and distributed by: